Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

KCI billing records subpoenaed

This article was originally published in The Gray Sheet

Executive Summary

Negative pressure wound therapy (NPWT) device maker Kinetic Concepts Inc. received a subpoena from the HHS Office of Inspector General in February regarding billing practices for its V.A.C. system at four regional durable medical equipment carriers, KCI disclosed in its annual report, filed with the Securities and Exchange Commission Feb. 26. The firm is in discussions with OIG regarding the scope of the subpoena and plans to cooperate. "The review is in its initial stages and we cannot predict the time frame in which it will be resolved," KCI said. OIG began investigating NPWT payment over-billing in 2005, released a report in 2007 and expects to publish another in 2009 (1"The Gray Sheet" Oct. 6, 2008, p. 9). "We do expect the government-led cost control efforts in the space to continue," J.P. Morgan analyst Michael Weinstein wrote in a Feb. 27 note

You may also be interested in...



HHS OIG Work Plan: FDA Oversight And DME, Inpatient Payments Make List

The Department of Health and Human Services Office of Inspector General 1outlined Oct. 1 more than 300 new and ongoing investigations on its to-do list for fiscal year 2009, including digging into how Medicare pays for durable medical equipment and examinations of hospital inpatient payments and FDA device oversight

Simplified Clinical Trial Transparency Rules To Go Live In The EU In June

A new version of the EU Clinical Trials Information System’s public portal will integrate the functionalities of the streamlined transparency rules. 

Top-Selling Drugs 2023: Pharma’s $60bn COVID-19 Cliff

Pfizer/BioNTech’s COVID-19 vaccine Comirnaty toppled after recording the highest ever annual sales for a pharmaceutical in 2022, while Novo Nordisk’s Ozempic climbed rapidly. But Merck & Co’s immuno-oncology blockbuster Keytruda was secure in the number one spot in 2023 as COVID-19 receded.

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

MT027162

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel